Biosplice Therapeutics, Inc. (Biosplice), a clinical-stage biotechnology company, announced potential structure-modifying highlights from an ongoing long-term extension study, OA-07, for its knee OA drug candidate, lorecivivint (LOR).
Results from the study continue to support the potential efficacy of multiple injections of lorecivivint in delaying structural progression and providing symptomatic benefic.
